<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00189644</url>
  </required_header>
  <id_info>
    <org_study_id>AERO-B2000</org_study_id>
    <nct_id>NCT00189644</nct_id>
  </id_info>
  <brief_title>6 FEC 100 Vs 4 FEC 100 Followed by 4 Taxol in N+ Breast Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association Européenne de Recherche en Oncologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Association Européenne de Recherche en Oncologie</source>
  <brief_summary>
    <textblock>
      The main objective of this randomized trial is to compare 6 FEC100 to 4 FEC100 + 4 Taxol in
      patients with resected node positive breast cancer. Main endpoint is disease free survival.
      Secondary endpoints are overall survival, time to local recurrence, time to distant
      metastases, and tolerance. A total of 840 patients have been included in the trial.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>6 FEC 100</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>4 FEC 100 followed by 4 Taxol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven cancer of the breast,

          -  Mastectomy or complete tumorectomy,

          -  Histologically proven homolateral, axillary lymph node involvement (at least 1 N+)

          -  Period between surgery (second operation in case of primarily incomplete resection)
             and the start of chemotherapy &lt; 2 months,

          -  Biological criteria (before the first FEC cycle):

               -  Neutrophils &gt;1.5 109 /L

               -  Platelets &gt;100 109/L

               -  Hemoglobin &gt;10 g/dl

               -  Creatininemia &lt;120 mmol/1

               -  Bilirubinemia &lt;1.5 Upper normal value

          -  Female patients over 18 years old

          -  Written and signed informed consent

          -  Performance Status less than or equal to 2 (WHO scale, see Annex IV)

        Exclusion Criteria:

          -  Prior chemotherapy or radiotherapy, including neo-adjuvant treatment for cancer of the
             breast,

          -  Bilateral breast cancer or history of contralateral breast cancer

          -  Cardiac history: cardiac insufficiency (LVEF &lt;50%) or coronary decompensation

          -  Pregnancy and breast-feeding (effective contraception is mandatory in the case of
             women of child-bearing potential)

          -  Inflammatory breast cancer

          -  Distant metastasis or supraclavicular adenopathy

          -  Benign pathology or history of malignant pathology accompanied by a life expectancy of
             less than two years

          -  Contra-indication to Anthracyclines, Cyclophosphamide, 5FU or Taxol

          -  Psychiatric pathology

          -  Patient participating in another trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal Piedbois, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Association Europeenne de Recherche en Oncologie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne-Chantal Braud, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Association Europeenne de Recherche en Oncologie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Serin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Association Europeenne de Recherche en Oncologie</affiliation>
  </overall_official>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>September 12, 2005</last_update_submitted>
  <last_update_submitted_qc>September 12, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

